Navigation Links
New TB Vaccine Passes Safety Trial
Date:4/8/2009

Experimental preparation was tested in people with latent infection,,

WEDNESDAY, April 8 (HealthDay News) -- An experimental tuberculosis vaccine called MVA85A proved safe in a small phase I clinical trial.

The study included 12 people with latent tuberculosis infection, which, when re-activated, can cause full-blown TB. It's believed that about a third of the world's population has this latent infection. The participants, who had no other complicating factors, such as hepatitis or HIV, were given the vaccine and then followed for a year.

The researchers concluded that the vaccine was safe, did not produce any immunopathology and was immunogenic in the patients. Some participants had side effects that included fever, headache, fatigue and mild concerns at the site of the vaccination.

The findings appear in the April 15 issue of the American Journal of Respiratory and Critical Care Medicine.

This study could be an important step forward in efforts to introduce a new vaccine to fight TB, according to the researchers, led by Dr. Helen McShane, of the University of Oxford in England. They noted that any new vaccine must be developed with latent TB infection in mind because it might decrease the effectiveness of new vaccines or worsen vaccine-related side effects.

"A more effective vaccine regimen than the currently available bacillus Calmette-Guerin would have a major impact on the global TB burden and, ultimately, will be the most efficient way to control this pandemic," the researchers wrote.

They noted that larger trials of the vaccine "are needed in TB endemic areas to assess the efficacy of this vaccine against the development of TB disease, but these results are very encouraging and justify the further development of this vaccine."

More information

The American Lung Association has more about TB.



-- Robert Preidt



SOURCE: American Thoracic Society, news release, April 7, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Dieter Luetticken Award 2008 Recognizes Development of New Vaccine Quality Control Assay
2. Hard To Treat Diseases (HTDS) Offers Hepatitis A Vaccine in India
3. U.S. Adults Needlessly Vulnerable to Vaccine-Preventable Diseases, According to New Report
4. Intercell Announces FDA Approval of IXIARO(R), a Vaccine Against Japanese Encephalitis
5. Wyeth Submits Marketing Application to FDA for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Toddlers
6. Hard to Treat Diseases (HTDS) clinical trial protocol for MMR Vaccine expected Q2 2009
7. Oral Yogurt Vaccine Could Blunt Ouch Factor
8. HPV Data May Aid Vaccines Effectiveness
9. Saving Vaccines with SensoTech's Breakthrough in Vaccine Temperature Monitoring
10. HARD TO TREAT DISEASES (HTDS) Influenca Vaccine (MEVAC-FLU) Enters Chilean Market
11. TB vaccine developed at McMaster University in Canada
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New TB Vaccine Passes Safety Trial
(Date:3/22/2017)... ... March 22, 2017 , ... ... California and Nevada and LABS, Inc., announced the future opening of a CLIA ... screening and serology testing used to determine the suitability of potential organ ...
(Date:3/22/2017)... ... ... Wash Tower Ltd. has released a series of six viral poo-related teaser ... standalone constant pressure bidet. , The videos in the series titled "The Adventures of ... well as on its social media pages. , Each video stars Arthur the Butler ...
(Date:3/22/2017)... ... 2017 , ... The Rett Syndrome Research Trust (RSRT) announced ... afflicts 350,000 individuals worldwide. Rett Syndrome is caused by alterations in a ... Following a normal infancy, Rett Syndrome takes effect in toddlerhood depriving children ...
(Date:3/22/2017)... ... 2017 , ... Drs. Jennifer Houck, Lauren Smith, Heather Johnson and the India ... need of skilled pediatric dentistry in Rock Hill, SC, without a referral. ... treatments, including cavities, sealants and fluoride applications, in a comfortable and fun environment. , ...
(Date:3/22/2017)... , ... March 22, 2017 , ... ... entered into a research collaboration to translate advances in basic neuroscience at the ... Blythedale and beyond. The collaboration seeks to improve movement, vision, and cognition impaired by ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital ... solutions, today reported financial and operational results for ... 31, 2016. 2016 Highlights ... compared to the full year 2015  ... year  Direct-to-consumer model launched in ...
(Date:3/22/2017)... today announced the appointment of Martyn Coombs as Chief ... ImaginAb, said "At ImaginAb we have exciting science and technology. Martyn ... business, particularly in commercializing and making step changes in the value ... our potential." ... Coombs is a recognized industry leader in nuclear medicine and imaging. ...
(Date:3/22/2017)... -- Ablation is the minimally invasive therapeutic tissue excision ... from cancerous or diseased tissue removal, to the ... fibrillation and others. The growing adoption of minimally ... and improvise existing ablation technologies for better patient ... is expected to grow at high single digit ...
Breaking Medicine Technology: